Document:

November
17, 2020

 

Advanced
Neural Dynamics, Inc.

3805
Old Easton Road

Doylestown,
PA 18902

Attn:
Douglas Brenneman, CEO

Via
email: dbrenneman@advneuraldynamics.com

 

Fox
Chase Chemical Diversity Center, Inc.

3805
Old Easton Road

Doylestown,
PA 18902

Attn:
Allen Reitz, CEO

Via
email: areitz@fc-cdci.com

 

RE:
Proposed Acquisition of Anticonvulsant IP Estate from Advanced Neural Dynamics, Inc. (“AND”) and Fox Chase
Chemical Diversity Center, Inc. (“Fox Chase”), collectively hereinafter referred to as the “AND-Fox Chase IP
Estate”

 

Gentlemen:

 

Further
to our recent discussion on Thursday, November 5, 2020, kindly accept the attached binding letter of intent (the “Letter
of Intent”) as a definitive outline of terms concerning the proposed acquisition of the AND-Fox Chase IP Estate. The
proposed acquisition and closing documents are collectively referred to in this Letter of Intent as the “Proposed Transaction”.

 

This
Binding Letter of Intent is a binding Letter of Intent meant to secure the conditions in the purchase agreement and other agreements
associated with the Proposed Transaction that are necessary for the full execution and delivery associated with the acquisition
of the AND-Fox Chase IP Estate. Such folio of agreements and documents (the “Definitive Closing Documents”)
include, but are not limited to: (a.) Technology Transfer and Purchase Agreement; (b.) Scientific Advisory Board Agreements; (c.)
Royalty Agreements (to include Reversion Rights); (d.) Stock Option Agreement for SAB; (e.) Patent Assignments; and (f.) Delivery
of Shares Evidenced by Statement of Account from Securities Transfer Corporation.

 

It
is anticipated that the full closing of this Proposed Transaction and execution of the Definitive Closing Documents take place
on or before 5:00 pm EST on Friday, December 11, 2020 (the “Closing Date”). In the event the aforementioned documentation
is made ready for execution prior to the Closing Date, all parties to this letter of intent will coordinate an earlier closing
date for the completion of the Proposed Transaction.

 

Please
review the attached Binding Term Sheet as these terms have been approved by the unaninmous consent of the board of directors of
Neuropathix, Inc. on November 10, 2020. If you have any additional questions or concerns, please do not hesitate to contact me
at (516) 782-6210 or via email at dean@neuropathix.com. I look forward to working with you both on this exciting portfolio of
technology.

 

 

Best
Regards

 

 

Dean
Petkanas, CEO

Neuropathix,
Inc.

 

    	 	1	 

     

    

 

BINDING
LETTER OF INTENT – TERMS AND CONDITIONS

 

Assets
to be Purchased:All patents, patents pending, trademarks, research and development materials, raw materials, (including
compounds in storage), chemical entities in the patent estate namely AND-302; AND-378; AND-383; AND-380; and AND-407, also referenced
in and by the following (the “Intellectual Property”): (a.) PCT WO2012/074784 A2 – “Novel Fluorinated
Sulfamides Exhibiting Neuroprotective Action and Their Method of Use”; (b.) US Patent 8,609,849 – “Novel Hydroxylated
Sulfamides Exhibiting Neuroprotective Action and Their Method of Use”; (c.) All compounds contained in an original provisional
patent relating to piperidine chemistry for refractory epilepsy, namely AND-378 and AND-383; and (d.) All technology described
in the Phase 2 SBIR Research Strategy pertaining to the aforementioned body of intellectual property and technology (the “Intellectual
Property” or “IP”).

 

	Purchaser
    / Acquiror:	Neuropathix,
    Inc
	 	 
	Sellers
    / Transferors:	Advanced
    Neural Dynamics, Inc. (“AND”); Douglas Brenneman (“Brenneman”); Fox Chase Chemical Diversity Center,
    Inc. (“Fox Chase”); and Allen B. Reitz (“Reitz”), (collectively, “Sellers” or “Transferors”)
	 	 
	Purchase
    Price of IP:	Six
    Hundred Thousand Dollars ($600,000)
	Form
    of Payment:	Neuropathix,
    Inc. Restricted Common Stock under Rule 144
	Exchange
    / Ticker:	OTCQB
    / NPTX
	Lock
    Up / Leak Out:	Under
    Rule 144
	 	 
	Full
    Terms / Covenants:	See:
    Addendum To Binding Letter of Intent

 

IN
WITNESS WHEREOF, on November 17, 2020, each of the Parties has executed this Binding Term Sheet governing the entry into and
deliver of the Definitive Closing Documents on or before the proposed Closing Date.

 

	PURCHASER / ACQUIROR:	 	 
	 	 	 
	NEUROPATHIX, INC.	 	 
	 	 	 
	 	 	 
	 	 	 
	By: Dean Petkanas, CEO	 	 
	 	 	 
	SELLERS / TRANSFERORS:	 	 
	 	 	 
	ADVANCED NEURAL DYNAMICS, INC.	 	DOUGLAS BRENNEMAN
	 	 	 
	 	 	 
	 	 	 
	By: Douglas Brenneman, CEO	 	In His Individual Capacity
	 	 	 
	FOX CHASE CHEMICAL DIVERSITY CENTER, INC.	 	ALLEN B. REITZ
	 	 	 
	 	 	 
	 	 	 
	By: Allen B. Reitz, CEO	 	In His Individual Capacity

 

 

    	 	2	 

     

    

 

ADDENDUM
TO TERM SHEET

 

	Terms
    of Acquisition / Binding Letter of Intent	Allen
                                         Reitz (“Reitz”) / Fox Chase Chemical Diversity Center, Inc. (“Fox Chase”)

         
	Douglas
    Brenneman (“Brenneman”) / Advanced Neural Dynamics (“AND”)
	Upfront
    Stock Grant in Consideration for the Sale of the Intellectual Property 	Reitz-Fox
                                         Chase Closing Date for issuance of shares to be scheduled on or before November 30, 2020,
                                         Reitz and/or Fox Chase shall be issued, 1,000,000 shares of Neuropathix, Inc. Common
                                         Stock, par value $.001 per share at a price of $.30 per share.

         

         

         
	Brenneman-AND
                                         Initial Closing Date for issuance of shares to be scheduled on or about January 5, 2021,
                                         Brenneman-AND shall be issued such amount of shares as equal to the compliment of $60,000
                                         divided by the average ten (10) day closing price of Neuropathix, Inc. Common Stock,
                                         par value $.001, prior to January 5, 2021 (the “Initial Installment Issuance”).

         

        In
        no case will the Initial Installment Issuance price be a price below $.30 per share or higher than $.60 per share.

         

        For
        subsequent closings, the share price for issuance of additional tranches of $60,000 (in year 2, 3, 4 and year 5) in value,
        will be determined by the average ten (10) day closing price of Neuropathix, Inc. Common Stock prior to each scheduled
        Installment Issuance Date. There will be no floor or ceiling in the range of price per share.

         

	Schedule
    of Installments 	Single
    Installment Issuance Date: On or before November 30, 2020.	Initial
                                         Installment Issuance Date: January 5, 2021.

        Second
        Installment Issuance Date: January 4, 2022.

        Third
        Installment Issuance Date: January 3, 2023.

        Fourth
        Installment Issuance Date: January 2, 2024.

        Fifth
        Installment Issuance Date: January 2, 2025.

         

	Cash
                                         Payments to Offset Tax on Shares

         

         

         

         

         

        Cash
        Payments to Offset

        Tax
        on Shares (cont’d)
	None.	Fifteen
                                         Thousand Five Hundred Dollars ($15,000) in cash annually, payable in quarterly installments
                                         of Three Thousand One Seven Hundred Fifty ($3,750), payable on March 30; June 30; September
                                         30 and December 31 of each year of an installment issuance (the “Quarterly Due
                                         Offset Payments”).

         

        Quarterly
        Due Offset payments are to be netted out against actual tax costs incurred based upon the issuance of Common Stock at
        a cost exceeding Doug Brenneman and/or AND’s basis.

         

	Ten
    Percent (10%) Penalty For Failure to Pay Offset Fees	None.	In
                                         the event a Quarterly Due Offset Payment is not made within thirty (30) days of the due
                                         date of such Quarterly Due Offset Payment (“Offset Default”), the amount
                                         payable will be Four Thousand One Hundred Twenty Five Dollars ($4,125) in total for each
                                         such Offset Default.

         

	Royalty
    Agreement Compensation	1%
                                         of Net Sales up to $500,000 per year, per participant (total of 2% of Net Sales up to
                                         a $1,000,000 per year maximum payout for both Reitz-Fox Chase and Brenneman-AND) (the
                                         “Royalty Fee”). The Royalty Fee shall continue in force in perpetuity but
                                         shall discontinue immediately upon an outright sale of the technology and/or any Reversion
                                         which eliminates on going revenue streams to Neuropathix, Inc.

         
	1%
    of Net Sales up to $500,000 per year, per participant (total of 2% of Net Sales up to a $1,000,000 per year maximum payout
    for both Reitz-Fox Chase and Brenneman-AND) (the “Royalty Fee”). The Royalty Fee shall continue in force in perpetuity
    but shall discontinue immediately upon an outright sale of the technology and/or any Reversion which eliminates on going revenue
    streams to Neuropathix, Inc.
	Reversion
                                         Rights

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

        Reversion
        Rights (cont’d)

         

         

         

         

         

         

         
	1%
                                         of future milestone payments received in connection with monetization of AND-Fox Chase
                                         Intellectual Property, per participant.

         

        Total
        of 2% of Reversion Rights for all participants.

         

        This
        includes receipt of payments by Neuropathix, Inc. from any third parties for option rights; initiation fees; milestone
        payments; up-front fees; minimum annual royalties (in absence of actual commercial royalty streams); licensing and/or
        sub-licensing fees; sales and marketing rights, or outright sale of the technology.

         

        The
        Reversion Right for percentage of payout does not include payouts on third party investments to Neuropathix, Inc. for
        any Joint Venture (JV) or Special Purpose Vehicle (SPV) designed to advance the AND-Fox Chase Intellectual Property for
        clinical development, clinical trials and/or commercialization efforts. However, the Royalty Rights remain in effect.

         

        For
        example: In such an event where a Third Party pays Neuropathix, Inc. an upfront license fee of $1,000,000 and also desires
        to establish a Joint Venture (JV) whereby it contributes additional R&D, pre-clinical and clinical development funding
        into Neuropathix directly or indirectly via a Special Purpose Vehicle (SPV) for clinical development, the collective Reversion
        Rights would still be payable and equal to 2% of $1,000,000, but not on any amounts designated solely for the use of proceeds
        directly attributed to R&D, pre-clinical and clinical development costs.

         

        However,
        the Royalty payments would remain 2% of the Net Sales receipts by Neuropathix, Inc. and only to such extent as Neuropathix,
        Inc. compliment (percentage of retention) resulting in revenue as adjusted for the definition of Net Sales receipts received
        by Neuropathix directly or passed through the JV / SPV to Neuropathix, Inc.
	1%
                                         of future milestone payments received in connection with monetization of AND-Fox Chase
                                         Intellectual Property, per participant.

         

        Total
        of 2% of Reversion Rights for all participants.

         

        This
        includes receipt of payments by Neuropathix, Inc. from any third parties for option rights; initiation fees; milestone
        payments; up-front fees; minimum annual royalties (in absence of actual commercial royalty streams); licensing and/or
        sub-licensing fees; sales and marketing rights, or outright sale of the technology.

         

        The
        Reversion Right for percentage of payout does not include payouts on third party investments to Neuropathix, Inc. for
        any Joint Venture (JV) or Special Purpose Vehicle (SPV) designed to advance the AND-Fox Chase Intellectual Property for
        clinical development, clinical trials and/or commercialization efforts. However, the Royalty Rights remain in effect.

         

        For
        example: In such an event where a Third Party pays Neuropathix, Inc. an upfront license fee of $1,000,000 and also desires
        to establish a Joint Venture (JV) whereby it contributes additional R&D, pre-clinical and clinical development funding
        into Neuropathix directly or indirectly via a Special Purpose Vehicle (SPV) for clinical development, the collective Reversion
        Rights would still be payable and equal to 2% of $1,000,000, but not on any amounts designated solely for the use of proceeds
        directly attributed to R&D, pre-clinical and clinical development costs.

         

        However,
        the Royalty payments would remain 2% of the Net Sales receipts by Neuropathix, Inc. and only to such extent as Neuropathix,
        Inc. compliment (percentage of retention) resulting in revenue as adjusted for the definition of Net Sales receipts received
        by Neuropathix directly or passed through the JV / SPV to Neuropathix, Inc.

         

	Scientific
                                         Advisory Board

         

         
	Allen
                                         Reitz would come on to our SAB for additional options of 100,000 shares for each year
                                         of SAB service (2 year agreement). Two (2) year SAB agreement with options for the purchase
                                         of 100,000 shares of common stock for each year of SAB service with 1⁄4 vesting
                                         up front and 1/24th remaining for each month of service thereafter execution.
                                         Options shall be priced based upon close of trading on the day prior to the entry into
                                         the SAB Agreement.

         
	Doug
                                         Brenneman would come on to our SAB for additional options of 100,000 shares for each
                                         year of SAB service (2 year agreement). Two (2) year SAB agreement with options for the
                                         purchase of 100,000 shares of common stock for each year of SAB service with 1⁄4
                                         vesting up front and 1/24th remaining for each month of service thereafter
                                         execution. Options shall be priced based upon close of trading on the day prior to the
                                         entry into the SAB Agreement.

         

	Additional
                                         Covenants

         
	(a.)
                                         Allen Reitz and Douglas Brenneman will maintain oversight and development of the
                                         intellectual property into and through clinical development.;

         

        (b.)
        Intellectual Property being purchased shall also entail future developments and patentability of AND-378; AND-383;
        AND-380; and AND-407, as well as extension of patentability and new technology advanced under AND-302; and/or related
        sulfamides, piperidines, and other derivatives and moieties therefrom the acquired AND-Fox Chase IP Estate.;

         

        (c.)
        The Intellectual Property being purchased is free and clear of any and all liens, third party rights and encumbrances,
        and is readily transferrable by the Transferors to the Acquiror; and

         

        (d.)
        Additional new patents would be filed on AND-378 (a piperidine – activity in the hippocampal kindling model,
        useful in refractory epilepsy.

         
	(a.)
                                         Allen Reitz and Douglas Brenneman will maintain oversight and development of the
                                         intellectual property into and through clinical development.;

         

        (b.)
        Intellectual Property being purchased shall also entail future developments and patentability of AND-378; AND-383;
        AND-380; and AND-407, as well as extension of patentability and new technology advanced under AND-302; and/or related
        sulfamides, piperidines, and other derivatives and moieties therefrom the acquired AND-Fox Chase IP Estate.;

         

        (c.)
        The Intellectual Property being purchased is free and clear of any and all liens, third party rights and encumbrances,
        and is readily transferrable by the Transferors to the Acquiror; and

         

        (d.)
        Additional new patents would be filed on AND-378 (a piperidine – activity in the hippocampal kindling model,
        useful in refractory epilepsy.

         

 

    	 	4EX-4.2

 Exhibit 4.2 

ROBLOX CORPORATION 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

This Amended and Restated Investors’ Rights Agreement (the “Agreement”) is made as of February 27, 2020, by
and among Roblox Corporation, a Delaware corporation (the “Company”), and the investors listed on Exhibit A hereto, each of which is herein referred to as an “Investor.” 

RECITALS 
 WHEREAS,
the Company and certain of the Investors are entering into a Series G Preferred Stock Purchase Agreement (the “Purchase Agreement”) of even date herewith pursuant to which the Company shall sell to such Investors and such
Investors shall purchase from the Company shares of the Company’s Series G Preferred Stock. A condition to the Investors’ obligations under the Series G Purchase Agreement is that the Company and the Investors enter into this Agreement in
order to provide the Investors (i) certain rights to register shares of Common Stock issuable upon conversion of the Series G Preferred Stock held by the Investors, (ii) certain rights to receive or inspect information pertaining to the
Company, and (iii) certain rights of first refusal with respect to future issuances of the Company’s securities. 

WHEREAS, certain of the Investors hold shares of the Company’s Series A Preferred Stock, Series B Preferred Stock, Series C
Preferred Stock, Series D Preferred Stock, Series D-1 Preferred Stock, Series E Preferred Stock, Series F Preferred Stock or Common Stock issued upon conversion thereof (the “Existing
Investors”) and possess certain registration rights, information rights, and other rights pursuant to an Amended and Restated Investors’ Rights Agreement dated as of June 19, 2018, among the Company and such Existing Investors
(the “Prior Rights Agreement”). 
 WHEREAS, the Company and the Existing Investors desire to amend and
restate the Prior Rights Agreement in its entirety. 
 WHEREAS, it is a further condition to the closing of the sale of the Series G
Preferred Stock pursuant to the Purchase Agreement that the Existing Investors holding at least a majority of the Common Stock issued or issuable upon conversion of the Company’s Series A Preferred Stock, Series B Preferred Stock, Series C
Preferred Stock, Series D Preferred Stock, Series D-1 Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock execute and deliver this Agreement and agree that this
Agreement will amend and restate the Prior Rights Agreement in its entirety. 
 NOW, THEREFORE, in consideration of the mutual
promises and covenants set forth herein, the Company and the Existing Investors hereby agree that the Prior Rights Agreement shall be superseded and replaced in its entirety by this Agreement, and the Company and the Investors hereby agree as
follows: 
 AGREEMENT 

The parties hereby agree as follows: 

1. Registration Rights. The Company and the Investors covenant and agree as follows: 

1.1 Definitions. For purposes of this Agreement: 

(a) “Common Stock” means the common stock of the Company. 

 (b) The terms “register,” “registered,” and
“registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Securities Act of 1933, as amended (the “Securities Act”),
and the declaration or ordering of effectiveness of such registration statement or document; 
 (c) The term “Registrable
Securities” means (i) Common Stock held by an Investor, (ii) shares of Common Stock issuable or issued upon conversion of the Preferred Stock, other than shares for which registration rights have terminated pursuant to
Section 1.15 hereof and (iii) any other shares of Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in
exchange for or in replacement of, the shares listed in (i) and (ii); provided, however, that the foregoing definition shall exclude in all cases any Registrable Securities sold by a person in a transaction in which his or her rights under this
Agreement are not assigned. Notwithstanding the foregoing, Common Stock or other securities shall only be treated as Registrable Securities if and so long as they have not been (A) sold to or through a broker or dealer or underwriter in a
public distribution or a public securities transaction, or (B) sold in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act under Section 4(a)(1) thereof so that all transfer restrictions,
and restrictive legends with respect thereto, if any, are removed upon the consummation of such sale; 
 (d) Subject to
Section 1.1(c)(ii), the term “Holder” means any person owning or having the right to acquire Registrable Securities or any assignee thereof in accordance with Section 1.12 of this Agreement; 

(e) The term “Form S-3” means
such form under the Securities Act as in effect on the date hereof or any successor form under the Securities Act that permits significant incorporation by reference of the Company’s subsequent public filings under the Securities
Exchange Act of 1934; 
 (f) The term “Preferred Stock” means the Series A Preferred Stock, Series B Preferred
Stock, Series C Preferred Stock, Series D Preferred Stock, Series D-1 Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock of the Company; 

(g) The term “Qualified IPO” has the meaning set forth in the Restated Certificate; 

(h) The term “Restated Certificate” means the Company’s Amended and Restated Certificate of Incorporation, as
amended from time to time; and 
 (i) The term “SEC” means the Securities and Exchange Commission. 

1.2 Requested Registration. 

(a) Subject to the conditions set forth in this Section 1.2, if the Company shall receive from any Holder or Holders of not less than
fifty percent (50%) of the Registrable Securities a written request that the Company effect any registration with respect to all or a part of the Registrable Securities (such request shall state the number of shares of Registrable Securities to be
disposed of by such Holder or Holders), the Company will: 
 (1) promptly give written notice of the proposed registration to all other
Holders; and 

  
 -2- 

 (2) as soon as practicable, file as expeditiously as reasonably possible, and in any event
no later than ninety (90) days following the receipt of such written request, and use its commercially reasonable efforts to effect such registration (including, without limitation, filing post-effective amendments, appropriate
qualifications under applicable blue sky or other state securities laws, and appropriate compliance with the Securities Act) and to permit or facilitate the sale and distribution of all of such Registrable Securities as are specified in such
request, together with all of the Registrable Securities of any Holder or Holders joining in such request as are specified in a written request received by the Company within twenty (20) days after such written notice from the Company is mailed
or delivered. 
 (b) Limitations on Requested Registration. The Company shall not be obligated to effect, or to take
any action to effect, any such registration pursuant to this Section 1.2: 
 (1) Prior to the earlier of one hundred eighty
(180) days following the effective date of the first registration statement filed by the Company covering an underwritten offering of any of its securities to the general public (or the subsequent date on which all market stand-off agreements applicable to the offering have terminated); 
 (2) If the Holder or Holders of not
less than fifty percent (50%) of the Registrable Securities, together with the holders of any other securities of the Company entitled to inclusion in such registration statement, propose to sell Registrable Securities and such other securities the
aggregate proceeds of which (after deduction for underwriter’s discounts and expenses related to the issuance) are less than $20,000,000; 

(3) In any particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting such
registration, qualification, or compliance, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(4) After the Company has initiated two such registrations pursuant to this Section 1.2 (counting for these purposes only
(x) registrations which have been declared or ordered effective and pursuant to which securities have been sold, and (y) withdrawn registrations); 

(5) During the period starting with the date sixty (60) days prior to the Company’s good faith estimate of the date of filing of,
and ending on a date one hundred eighty (180) days after the effective date of, a Company-initiated registration; provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration
statement to become effective; 
 (6) If the Holders propose to dispose of shares of Registrable Securities that may be registered on Form S-3 pursuant to a request made under Section 1.4; 
 (7) If the Holders do not request that such
offering be firmly underwritten by underwriters selected by the Holders (subject to the consent of the Company); or 
 (8) If the Company
and the Holders are unable to obtain the commitment of the underwriter described in clause (b)(7) above to firmly underwrite the offer. 

(c) Deferral. If (i) in the good faith judgment of the board of directors of the Company, the filing of a
registration statement covering the Registrable Securities would be materially detrimental to the Company and the board of directors of the Company concludes, as a result, that it is in the best interests of the Company to defer the filing of such
registration statement at such time, and (ii) the 

  
 -3- 

 
Company shall furnish to such Holders a certificate signed by the President of the Company stating that in the good faith judgment of the board of directors of the Company, it would be materially
detrimental to the Company for such registration statement to be filed in the near future and that it is, therefore, in the best interests of the Company to defer the filing of such registration statement, then (in addition to the limitations set
forth in Section 1.2(b)(5) above) the Company shall have the right to defer such filing for a period of not more than one hundred ninety (190) days after receipt of the request of the Holders, and, provided further, that the Company shall
not defer its obligation in this manner more than twice in any twelve-month period; and provided further, that the Company shall not register any securities for the account of itself or any other shareholder during any such ninety (90) day
period (other than a registration relating solely to employee benefit plans, a registration relating to the offer and sale of debt securities, or a registration relating to a corporate reorganization or other Rule 145 transaction). 

(d) Underwriting. Unless the Registrable Securities may be registered by the Company on
Form S-3, the right of any Holder to include all or any portion of its Registrable Securities in such registration pursuant to this Section 1.2 shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities to the extent provided herein. If the Company shall request inclusion in any registration pursuant to Section 1.2 of securities being sold for its
own account, or if other persons shall request inclusion in any registration pursuant to Section 1.2, the Holders shall, on behalf of all Holders, offer to include such securities in the underwriting and such offer shall be conditioned upon the
participation of the Company or such other persons in such underwriting and the inclusion of the Company’s and such person’s other securities of the Company and their acceptance of the further applicable provisions of this Section 1
(including Section 1.13). The Company shall (together with all Holders proposing to distribute their securities through such underwriting) enter into an underwriting agreement in customary form with the representative of the underwriter or
underwriters selected for such underwriting by a majority-in-interest of the Holders, which underwriters are reasonably acceptable to the Company. 

Notwithstanding any other provision of this Section 1.2, if the underwriters advise the Holders in writing that marketing factors require
a limitation on the number of shares to be underwritten, the number of Registrable Securities that may be so included shall be allocated among all Holders requesting to include Registrable Securities in such registration statement based on the
pro rata percentage of Registrable Securities held by such Holders, assuming conversion; provided, however, that the number of shares of Registrable Securities to be included in such underwriting and registration shall not be reduced unless
all other securities of the Company are first entirely excluded from the underwriting and registration. For purposes of the preceding parenthetical concerning apportionment, for any selling stockholder which is a holder of Registrable Securities and
which is a venture capital fund, partnership or corporation, the affiliated venture capital funds, partners, retired partners, members, former members and stockholders of such holder, or the estates and family members of any such partners and
retired partners, members and former members and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “selling stockholder,” and any pro-rata reduction with
respect to such “selling stockholder” shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “selling stockholder,” as defined in this sentence. 

If a person who has requested inclusion in such registration as provided above does not agree to the terms of any such underwriting, such
person shall be excluded therefrom by written notice from the Company, the underwriter or the Holders. The securities so excluded shall also be withdrawn from registration. Any Registrable Securities or other securities excluded or withdrawn from
such underwriting shall also be withdrawn from such registration. If shares are so withdrawn from the registration and if the number of shares to be included in such registration was previously reduced as a result of marketing factors pursuant to
this Section 1.2, then the Company shall then offer to all Holders who have retained rights to include securities in the registration the right to include additional Registrable Securities in the registration in an aggregate amount equal to the
number of shares so withdrawn, with such shares to be allocated among such Holders requesting additional inclusion, as set forth above. 

  
 -4- 

 1.3 Company Registration. If (but without any obligation to do so) the Company
proposes to register (including for this purpose a registration effected by the Company for stockholders other than the Holders) any of its stock under the Securities Act in connection with the public offering of such securities solely for cash
(other than a registration relating solely to the sale of securities to participants in a Company stock plan or a transaction covered by Rule 145 under the Securities Act, a registration in which the only stock being registered is Common Stock
issuable upon conversion of debt securities which are also being registered, or any registration on any form which does not include substantially the same information as would be required to be included in a registration statement covering the sale
of the Registrable Securities), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of a Holder given within ten (10) days after mailing of such notice by the Company in
accordance with Section 4.4, the Company shall, subject to the provisions of Section 1.8, cause to be registered under the Securities Act all of the Registrable Securities that each such Holder has requested to be registered. 

1.4 Form S-3 Registration. In case the Company shall receive from any Holder or Holders
of not less than fifty percent (50%) of the Registrable Securities then outstanding a written request or requests that the Company effect a registration on Form S-3 (or any similar form) and any related
qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will: 

(a) promptly give written notice of the proposed registration, and any related qualification or compliance, to all other Holders; and 

(b) as soon as practicable, and in any event no later than forty-five (45) days following the receipt of such written request, effect
such registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all of such Holder’s or Holders’ Registrable Securities as are specified in such request,
together with all of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within 15 days after receipt of such written notice from the Company; provided, however, that the
Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this Section 1.4: (i) if Form S-3 (or any similar form) is not available for such
offering by the Holders; (ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate
price to the public (net of any underwriters’ discounts or commissions) of less than $2,000,000; (iii) if the Company shall furnish to the Holders a certificate signed by the President of the Company stating that in the good faith judgment
of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such Form S-3 Registration to be effected at such time, in which event the Company shall
have the right to defer the filing of the Form S-3 (or any similar form) registration statement for a period of not more than 90 days after receipt of the request of the Holder or Holders under this
Section 1.4; provided, however, that the Company shall not utilize this right more than once in any twelve month period; (iv) if the Company has, within the twelve (12) month period preceding the date of such request, already effected
two (2) registrations on Form S-3 for the Holders pursuant to this Section 1.4; (v) in any particular jurisdiction in which the Company would be required to qualify to do business or to
execute a general consent to service of process in effecting such registration, qualification or compliance; or (vi) during the period ending one hundred eighty (180) days after the effective date of a registration statement for a
Qualified IPO. 

  
 -5- 

 1.5 Obligations of the Company. Whenever required under this Section 1 to
effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) Prepare and file
with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the
Registrable Securities registered thereunder, keep such registration statement effective for up to one hundred twenty (120) days. The Company shall not be required to file, cause to become effective or maintain the effectiveness of any
registration statement that contemplates a distribution of securities on a delayed or continuous basis pursuant to Rule 415 under the Securities Act. 

(b) Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with
such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement for up to one hundred twenty (120) days. 

(c) Furnish to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of
the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 

(d) To the extent the Company is a well-known seasoned issuer (as defined in Rule 405 under the Securities Act) (a
“WKSI”) at the time any request for registration is submitted to the Company in accordance with Section 1.4, (i) if so requested, file an automatic shelf registration statement (as defined in Rule 405 under the
Securities Act) (an “automatic shelf registration statement”) to effect such registration, and (ii) remain a WKSI (and not become an ineligible issuer (as defined in Rule 405 under the Securities Act)) during the period
during which such automatic shelf registration statement is required to remain effective in accordance with this Agreement. 
 (e) Use its
commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the
Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions. 

(f) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 

(g) Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing, and following such notification promptly prepare and furnish to such seller a reasonable number
of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such shares, such prospectus shall not include an untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing;. 

  
 -6- 

 (h) Cause all such Registrable Securities registered hereunder to be listed on each
securities exchange on which similar securities issued by the Company are then listed. 
 (i) If at any time when the Company is required to
re-evaluate its WKSI status for purposes of an automatic shelf registration statement used to effect a request for registration in accordance with Section 1.4 (i) the Company determines that it is
not a WKSI, (ii) the registration statement is required to be kept effective in accordance with this Agreement, and (iii) the registration rights of the applicable Holders have not terminated, promptly amend the registration statement onto
a form the Company is then eligible to use or file a new registration statement on such form, and keep such registration statement effective in accordance with the requirements otherwise applicable under this Agreement. 

(j) If (i) a registration made pursuant to a shelf registration statement is required to be kept effective in accordance with this
Agreement after the third anniversary of the initial effective date of the shelf registration statement, (ii) the registration rights of the applicable Holders have not terminated and (iii) the Company is eligible at such time to file a
shelf registration statement on Form S-3, file a new registration statement with respect to any unsold Registrable Securities subject to the original request for registration prior to the end of the three year
period after the initial effective date of the shelf registration statement, and keep such registration statement effective in accordance with the requirements otherwise applicable under this Agreement. 

(k) Provide a transfer agent and registrar for all Registrable Securities registered hereunder and a CUSIP number for all such Registrable
Securities, in each case not later than the effective date of such registration. 
 (l) Use its commercially reasonable efforts to furnish,
at the request of any Holder requesting registration of Registrable Securities pursuant to this Section 1, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to
this Section 1, if such securities are being sold through underwriters, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to
underwriters in an underwritten public offering, addressed to the underwriters and to the Holders requesting registration of Registrable Securities and (ii) a letter dated such date, from the independent certified public accountants of the
Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable
Securities. 
 1.6 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action
pursuant to this Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of
disposition of such securities as shall be required to effect the registration of such Holder’s Registrable Securities. The Company shall have no obligation with respect to any registration requested pursuant to Section 1.4 of this
Agreement if, as a result of the application of the preceding sentence, the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the number of shares
or the anticipated aggregate offering price required to originally trigger the Company’s obligation to initiate such registration as specified in subsection 1.4(b)(2), whichever is applicable. 

1.7 Expenses of Registration. 

(a) Requested Registration. All expenses other than underwriting discounts and commissions incurred in connection with
registrations, filings or qualifications of Registrable Securities pursuant to Section 1.2 for each Holder (which right may be assigned as provided in 

  
 -7- 

 
Section 1.12), including (without limitation) all registration, filing, and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company and the
reasonable fees and disbursements of one counsel for the selling Holder or Holders selected by them (such fees and disbursements not to exceed $50,000 for any registered offering), which approval shall not be unreasonably withheld, shall be borne by
the Company. 
 (b) Company Registration. All expenses other than underwriting discounts and commissions incurred in
connection with registrations, filings or qualifications of Registrable Securities pursuant to Section 1.3 for each Holder (which right may be assigned as provided in Section 1.12), including (without limitation) all registration, filing,
and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for the selling Holder or Holders selected by them (such fees and disbursements
not to exceed $50,000 for any registered offering), which approval shall not be unreasonably withheld, shall be borne by the Company. 
 (c)
Registration on Form S-3. All expenses other than underwriting discounts and commissions incurred in connection with a registration requested pursuant to Section 1.4, including (without
limitation) all registration, filing, and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for the selling Holder or Holders selected
by them (such fees and disbursements not to exceed $50,000 for any registered offering), which approval shall not be unreasonably withheld, shall be borne by the Company. 

1.8 Underwriting Requirements. In connection with any offering involving an underwriting of shares of the Company’s capital stock,
the Company shall not be required under Section 1.3 to include any of the Holders’ securities in such underwriting unless they accept the terms of the underwriting as agreed upon between the Company and the underwriters selected by it (or
by other persons entitled to select the underwriters), and then only in such quantity as the underwriters determine in their sole discretion will not jeopardize the success of the offering by the Company. If the total amount of securities, including
Registrable Securities, requested by stockholders to be included in such offering exceeds the amount of securities sold other than by the Company that the underwriters determine in their sole discretion is compatible with the success of the
offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters determine in their sole discretion will not jeopardize the success of the offering
(the securities so included to be apportioned pro rata among the selling stockholders according to the total amount of securities entitled to be included therein owned by each selling stockholder or in such other proportions as shall mutually be
agreed to by such selling stockholders) but in no event shall the amount of securities of the selling Holders included in the offering be reduced below twenty percent (20%) of the total amount of securities included in such offering, unless such
offering is the initial public offering of the Company’s securities, in which case, the selling stockholders may be excluded if the underwriters make the determination described above and no other stockholder’s securities are included. For
purposes of the preceding parenthetical concerning apportionment, for any selling stockholder which is a holder of Registrable Securities and which is a venture capital fund, partnership or corporation, the affiliated venture capital funds,
partners, retired partners, members, former members, and stockholders of such holder, or the estates and family members of any such partners and retired partners, members and former members and any trusts for the benefit of any of the foregoing
persons shall be deemed to be a single “selling stockholder,” and any pro-rata reduction with respect to such “selling stockholder” shall be based upon the aggregate amount of shares
carrying registration rights owned by all entities and individuals included in such “selling stockholder,” as defined in this sentence. 

  
 -8- 

 1.9 Delay of Registration. No Holder shall have any right to obtain or seek an
injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1. 

1.10 Indemnification. In the event any Registrable Securities are included in a registration statement under this Section 1: 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, the partners, officer and directors of each
Holder, any underwriter (as defined in the Securities Act) for such Holder and each other person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses,
claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a “Violation”): (i) any untrue statement or alleged
untrue statement of a material fact contained or incorporated by reference in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or
alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any
state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law; and the Company will pay to each such Holder, each of its partners, officers and directors, underwriter or controlling
person, as incurred, any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this
subsection 1.10(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor
shall the Company be liable to any Holder, underwriter or controlling person for any such loss, claim, damage, liability, or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with
written information furnished expressly for use in connection with such registration by any such Holder, underwriter or controlling person. 

(b) To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, each of its
directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of the Securities Act, any underwriter, any other Holder selling securities in such registration statement
and any controlling person of any such underwriter or other Holder, against any losses, claims, damages, or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Securities Act, the Exchange Act or other
federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance
upon and in conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will pay, as incurred, any legal or other expenses reasonably incurred by any person intended to be
indemnified pursuant to this subsection 1.10(b), in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this subsection 1.10(b) shall
not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided, that in no event shall any
indemnity under this subsection 1.10(b) exceed the net proceeds from the offering received by such Holder. 

  
 -9- 

 (c) Promptly after receipt by an indemnified party under this Section 1.10 of notice
of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.10, deliver to the indemnifying party a written
notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof
with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties which may be represented without conflict by one counsel) shall have the right to retain one separate
counsel, with the reasonable fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests
between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its
ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 1.10, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability
that it may have to any indemnified party otherwise than under this Section 1.10. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment
or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. Each Indemnified Party
shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and as shall be reasonably required in connection with defense of such claim and litigation resulting therefrom. 

(d) If the indemnification provided for in this Section 1.10 is held by a court of competent jurisdiction to be unavailable to an
indemnified party with respect to any loss, liability, claim, damage or expense referred to herein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such
indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection
with the statements or omissions that resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations; provided, that in no event shall any contribution by a Holder under this Subsection 1.10(d)
exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by such Holder. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access
to information, and opportunity to correct or prevent such statement or omission. 
 (e) Notwithstanding the foregoing, to the extent that
the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement
shall control. 
 (f) The obligations of the Company and Holders under this Section 1.10 shall survive the completion of any offering
of Registrable Securities in a registration statement under this Section 1, and otherwise. 
 1.11 Reports Under Securities Exchange
Act of 1934. With a view to making available to the Holders the benefits of Rule 144 promulgated under the Securities Act and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to
the public without registration or pursuant to a registration on Form S-3, the Company agrees to: 

  
 -10- 

 (a) make and keep public information available, as those terms are understood and defined
in SEC Rule 144, at all times after ninety (90) days after the effective date of the first registration statement filed by the Company for the offering of its securities to the general public so long as the Company remains subject to the
periodic reporting requirements under Sections 13 or 15(d) of the Exchange Act; 
 (b) take such action, including the voluntary
registration of its Common Stock under Section 12 of the Exchange Act, as is necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities, such action to be taken
as soon as practicable after the end of the fiscal year in which the first registration statement filed by the Company for the offering of its securities to the general public is declared effective; 

(c) file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange
Act; and 
 (d) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written
statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed by the Company), the Securities Act and
the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so
qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of
any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form. 
 1.12
Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this Section 1 above may be assigned (but only with all related obligations) by a Holder to a transferee or assignee that
(i) is an Affiliate (as defined in Section 3.1(d)) of a Holder or (ii) after such transfer, holds at least 6,000,000 shares of such securities (as may be adjusted from time to time for stock splits, stock dividends, combinations,
subdivisions, recapitalizations and the like) (or all of the Holders’ Registrable Securities, if less), provided the Company is, within a reasonable time frame after such transfer, furnished with written notice of the name and address of such
transferee or assignee and the securities with respect to which such registration rights are being assigned; and provided, further, that such assignment shall be effective only if immediately following such transfer the further disposition of such
securities by the transferee or assignee is restricted under the Securities Act. For the purposes of determining the number of shares of Registrable Securities held by a transferee or assignee, the holdings of transferees and assignees of a
partnership who are partners or retired partners of such partnership (including spouses and ancestors, lineal descendants and siblings of such partners or spouses who acquire Registrable Securities by gift, will or intestate succession) shall be
aggregated together and with the partnership; provided that all assignees and transferees who would not qualify individually for assignment of registration rights shall have a single
attorney-in-fact for the purpose of exercising any rights, receiving notices or taking any action under Section 1. 

1.13 Amendment of Registration Rights. Any provision of this Section 1 may be amended and the observance thereof may be waived
(either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Holders of a majority of the Registrable Securities then outstanding. Any amendment or waiver effected in
accordance with this Section 1.13 shall be binding upon each Holder and the Company. By acceptance of any benefits under this Section 1, Holders of Registrable Securities hereby agree to be bound by the provisions hereunder. 

  
 -11- 

 1.14 Lock-Up Agreement. 

(a) Lock-Up Period; Agreement. In connection with the initial public offering of the
Company’s securities and upon request of the Company or the underwriters managing such offering of the Company’s securities, each Holder agrees not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise
dispose of any securities of the Company, however or whenever acquired (other than those included in the registration or acquired thereafter in open market transactions) without the prior written consent of the Company or such underwriters, as the
case may be, for a period of up to one hundred eighty (180) day period commencing upon the effective date of such registration, or, if the Company is not an “Emerging Growth Company” as defined under the Jumpstart Our
Business Startups (JOBS) Act of 2012 at the time of its initial public offering, such other period, not to exceed twenty (20) days, as may be requested by the Company or such managing underwriters to accommodate regulatory restrictions on
(i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2241, or any successor provisions or amendments thereto,
and to execute an agreement reflecting the foregoing as may be requested by the underwriters at the time of the Company’s initial public offering. 

(b) Limitations. The obligations described in Section 1.14(a) shall apply only to the Company’s initial public offering and
only if all officers, directors and one-percent security holders of the Company enter into similar agreements. The obligations described in Section 1.14(a) shall not apply to a registration relating
solely to employee benefit plans, or to a registration relating solely to a transaction pursuant to Rule 145 under the Securities Act. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the
underwriters shall apply to all Holders subject to such agreements pro rata based on the number of shares subject to such agreements. 
 (c)
Stop-Transfer Instructions. In order to enforce the foregoing covenants, the Company may impose stop-transfer instructions with respect to the securities of each Holder (and the securities of every other person subject to the restrictions in
Section 1.14(a)). 
 (d) Transferees Bound. Each Holder agrees that it will not transfer securities of the Company prior to the
end of such lock-up period unless each transferee agrees in writing to be bound by all of the provisions of this Section 1.14. 

1.15 Termination of Registration Rights. No Holder shall be entitled to exercise any right provided for in Section 1.3 or
Section 1.4 after the earliest of (i) five years following the consummation of a Qualified IPO, (ii) such time as the Company is traded on a securities exchange or the Nasdaq Stock Market and Rule 144 or another similar exemption
under the Securities Act is available for the sale of all of such Holder’s shares during a three-month period without registration, (iii) upon termination of the entire Agreement upon a change in
control of the Company, as provided in Section 4.1, or (iv) upon the consummation of a Deemed Liquidation Event (as defined in the Restated Certificate). 

1.16 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of a majority of the outstanding Registrable Securities, enter into any agreement with any holder or prospective holder of any securities of the Company which would allow such holder or prospective holder to include
such securities in any registration filed under Section 1.3 hereof, unless under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of his
securities will not reduce (except on a pro rata basis with such securities) the amount of the Registrable Securities of the Holders which is included. 

  
 -12- 

 2. Covenants of the Company. 

2.1 Delivery of Financial Statements. The Company shall deliver to each Holder of at least 10,000,000 shares of Registrable Securities
(as may be adjusted from time to time for stock splits, stock dividends, combinations, subdivisions, recapitalizations and the like) (each a “Significant Holder”), provided, however, that neither TCH Scarlet
Limited nor any of its Affiliates (as defined below) shall be considered a Significant Holder irrespective of their ownership of shares of Registrable Securities for purposes of this Section 2.1 and Section 2.2: 

(a) as soon as practicable, but in any event not later than one hundred eighty (180) days after the end of a fiscal year of the Company,
an income statement for such fiscal year, a balance sheet of the Company and statement of stockholder’s equity as of the end of such year, and a statement of cash flows for such year, each prepared in accordance with U.S. generally accepted
accounting principles consistently applied, audited and certified by independent public accountants of recognized national standing selected by the Company; 

(b) as soon as practicable, but in any event not later than (i) forty five (45) days after the end of a specified one of the first
three quarters of a fiscal year of the Company or (ii) upon the request of a Significant Holder, a profit or loss statement, a statement of cash flows for such fiscal quarter and a balance sheet as of the end of such fiscal quarter; 

(c) within five (5) days of its approval by the Board of Directors of the Company, an operating plan for such fiscal year; 

(d) Promptly following written request by a Significant Holder, a detailed capitalization table of the Company, including the number of shares
of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock (which, to the extent applicable, shall include the face amount, issue date, maturity date, interest rate, conversion discount,
change of control premium and valuation cap) outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock, including issued stock options and
stock options reserved for issuance, if any, all in sufficient detail for such Significant Holder to calculate its percentage equity ownership in the Company; and 

(e) such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Significant
Holder may from time to time reasonably request (including, but not limited to, full reports of independent third-party valuation firms for purposes of compliance with Section 409A of the Internal Revenue Code and summary and detailed
capitalization reports); provided, however, that the Company shall not be obligated under this Section 2.1(e) to provide information (a) that the Board of Directors reasonably determines in good faith to be a trade secret or classified
information or (b) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company,
then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries; provided, however, that in
no event shall any Holder that is a Foreign Investor (as defined in the Purchase Agreement) be permitted to obtain information pursuant to this Section 2.1 that would constitute “material nonpublic technical information” (as defined
in Section 721 of the U.S. Defense Production Act of 1950, as amended, including any implementing regulations (the “DPA”)) except to the extent such Foreign Investor already had rights to access such information prior to
the date of this Agreement. 

  
 -13- 

 2.2 Inspection. The Company shall permit each Significant Holder (except for
Significant Holders reasonably deemed by Board of Directors of the Company to be a competitor of the Company, provided that, a Holder that is a venture capital fund, institutional investor or charitable trust shall not be determined a
competitor solely as a result of its investment in other companies), at such Holder’s expense, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances
and accounts with its officers, all at such reasonable times as may be requested by the Investor; provided, however, that the Company shall not be obligated pursuant to this Section 2.2 with respect to a competitor of the Company or with
respect to information (a) that the Board of Directors reasonably determines in good faith to be a trade secret or classified information or (b) the disclosure of which would adversely affect the attorney-client privilege between the
Company and its counsel; provided, further, that in no event shall any Holder that is a Foreign Investor (as defined in the Purchase Agreement) be permitted to obtain information pursuant to this Section 2.2 that would constitute “material
nonpublic technical information” (as defined in the DPA) except to the extent such Foreign Investor already had rights to access such information prior to the date of this Agreement. 

2.3 409A Valuation. The Company shall obtain a third party valuation of its Common Stock for the purposes of Section 409A of the
Internal Revenue Code as required and in any event no less than once per annum. 
 2.4 Termination of Covenants. The covenants set
forth in Sections 2.1 through Section 2.3 shall terminate as to each Holder and be of no further force or effect on the earliest of (i) immediately prior to the consummation of a Qualified IPO, or (ii) upon termination of the
entire Agreement upon a change in control of the Company, as provided in Section 4.1, (iii) when the Company first becomes subject to the periodic reporting requirements of Sections 13 or 15(d) of the Exchange Act or (iv) upon a
liquidation, dissolution or winding up of the Company. 
 3. Right of First Refusal. 

3.1 Right of First Refusal to Significant Holders. The Company hereby grants to each Significant Holder, the right of first refusal to
purchase its pro rata share of New Securities (as defined in this Section 3.1) which the Company may, from time to time, propose to sell and issue after the date of this Agreement. A Significant Holder’s pro rata share, for purposes of
this right of first refusal, is equal to the ratio of (a) the number of shares of Common Stock owned by such Significant Holder immediately prior to the issuance of New Securities (assuming full conversion and exercise of all outstanding
convertible securities, rights, options and warrants, directly or indirectly, into Common Stock held by said Significant Holder) to (b) the total number of shares of Common Stock outstanding immediately prior to the issuance of New Securities
(assuming full conversion and exercise of all outstanding convertible securities, rights, options and warrants, directly or indirectly, held by all of the Significant Holders). This right of first refusal shall be subject to the following
provisions: 
 (a) “New Securities” shall mean any capital stock (including Common Stock and/or Preferred Stock) of
the Company whether now authorized or not, and rights, convertible securities, options or warrants to purchase such capital stock, and securities of any type whatsoever that are, or may become, exercisable or convertible into capital stock; provided
that the term “New Securities” does not include the issuances or deemed issuances excluded from the definition of “Additional Stock” pursuant to Article IV, Section 4(d)(i)(B) of the Restated Certificate. 

(b) In the event the Company proposes to undertake an issuance of New Securities, it shall give each Significant Holder written notice of its
intention, describing the type of New Securities, and their price and the general terms upon which the Company proposes to issue the same. Each Significant Holder shall have ten (10) days after any such notice is given or delivered to agree to
purchase such Significant Holder’s pro rata share of such New Securities, in substantially the form attached hereto as Schedule 1, and stating therein the quantity of New Securities to be purchased. 

  
 -14- 

 (c) In the event the Significant Holders fail to exercise fully the right of first refusal
within said ten (10) day period (the “Election Period”), the Company shall have ninety (90) days thereafter to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall be
closed, if at all, within ninety (90) days from the date of said agreement) to sell that portion of the New Securities with respect to which the Significant Holders’ right of first refusal option set forth in this Section 3.1 was not
exercised, at a price and upon terms no more favorable to the purchasers thereof than specified in the Company’s notice to Significant Holders delivered pursuant to Section 3.1. In the event the Company has not sold within such ninety
(90) day period following the Election Period, or such ninety (90) day period following the date of said agreement, the Company shall not thereafter issue or sell any New Securities, without first again offering such securities to the
Significant Holders in the manner provided in this Section 3.1. 
 (d) Each Significant Holder shall be entitled to assign or apportion
its right of first refusal among its Affiliates (as defined below) who have agreed to be bound by the terms of this Agreement in such proportions as it deems appropriate; provided that, for the purposes of this Section 3, any Significant Holder
who has made any such assignment or apportionment shall be deemed to act as the agent of all of its Affiliates to whom such assignment or apportionment has been made and any notice delivered to, or received from, any such Significant Holder shall be
deemed to have been delivered to, or received from, all such Affiliates. For purposes hereof, the term “Affiliate” shall mean (a) a parent, subsidiary or other affiliate of the Holder, if the Holder is a corporation,
(b) any of the Holder’s partners, members or other equity owners, or retired partners, former members or other equity owners, or to the estate of any of the Holder’s partners, members or other equity owners or retired partners, former
members or other equity owners, or (c) a venture capital fund that is controlled by or under common control with one or more general partners or managing members of, or shares the same management company or advisory company with, the Holder.

 (e) The right of first refusal granted under this Agreement shall expire upon the Company’s Initial Public Offering. 

(f) Consistent with Section 4.12 and notwithstanding anything in this Section 3.1, in no event shall any Significant Holder that is
a Foreign Investor (as defined in the Purchase Agreement) be permitted to purchase any amount of new securities that would grant such Foreign Investor or purchaser an equity interest in excess of 9.9% of total outstanding voting securities in the
Company. 
 4. Miscellaneous. 

4.1 Termination of Entire Agreement Upon Change of Control. This Agreement shall terminate, and have no further force and effect, when
the Company shall sell, convey, or otherwise dispose of all or substantially all of its property or business or merge with or into or consolidate with any other corporation (other than a wholly-owned subsidiary) or effect any other transaction or
series of related transactions (other than equity financing transactions for the purpose of raising capital) in which the stockholders of the Company immediately preceding the transaction or series of related transactions hold, after the transaction
or series of related transactions, less than 50% of the voting power of the resulting corporation or entity and less than 50% of the voting power of its ultimate corporate parent, if applicable, provided that this Agreement shall not be terminated
following a merger effected solely for the purpose of changing the domicile of the Company. 
 4.2 Successors and Assigns. Except as
otherwise provided in this Agreement, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties (including transferees of any of the Preferred Stock).
Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement,
except as expressly provided in this Agreement. 
  

  
 -15- 

 4.3 Amendments and Waivers. Except as provided in Section 4.10, any term of this
Agreement may be amended or waived only with the written consent of the Company and the holders of a majority of the Registrable Securities; provided, that, this Agreement may not be amended or terminated and the observance of any term hereof may
not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion; provided further that, notwithstanding any waiver of Section 3
in connection with the issuance of New Securities, in the event any Significant Holder actually purchases any New Securities in any such issuance of New Securities by the Company, then each Significant Holder shall be permitted to participate in
such offering on a pro rata basis (based on the level of participation of the Significant Holders purchasing the largest portion of such Significant Holder’s pro rata share), in accordance with the other provisions (including notice and
election periods) set forth in Section 3. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each party to the Agreement, whether or not such party has signed such amendment or waiver, each future holder of
all such Registrable Securities, and the Company. The Company shall give prompt written notice of any amendment, modification or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment,
modification, termination or waiver. No waivers of or exceptions to any term, condition or provision of this Agreement, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition
or provision. The Prior Rights Agreement is hereby amended and restated in its entirety upon the execution and delivery of this Agreement by the Company and the holders of a majority of the Registrable Securities. 

4.4 Notices. Unless otherwise provided, all notices and other communications required or permitted hereunder shall be in writing and
shall be mailed by registered or certified mail, postage prepaid, or otherwise delivered by hand or by courier (including a recognized overnight delivery service), or by facsimile addressed (a) if to an Investor, at such Investor’s address
set forth in Exhibit A, or at such other address as such Investor shall have furnished to the Company in writing, or (b) if to the Company, one copy shall be sent to 970 Park Place, San Mateo, CA 94403; Attn: Mark Reinstra, with a second
copy to Michael Coke, Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304; fax: 650-493-9300. Each such notice or other
communication shall for all purposes of this Agreement be treated as effective or having been given when delivered if delivered personally or by courier or sent by facsimile, or, if sent by mail, at the earlier of its receipt or 72 hours after the
same has been deposited in a regularly maintained receptacle for the deposit of the United States mail, addressed and mailed as aforesaid. 

4.5 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to
renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (a) such provision shall be excluded from this Agreement, (b) the balance of the
Agreement shall be interpreted as if such provision were so excluded and (c) the balance of the Agreement shall be enforceable in accordance with its terms. 

4.6 Governing Law. This Agreement and all acts and transactions pursuant hereto shall be governed, construed and interpreted in
accordance with the laws of the State of California, without giving effect to principles of conflicts of laws. 
 4.7 Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile copies of manual signatures, if delivered, shall be effective
and binding as original manual signatures. 

  
 -16- 

 4.8 Titles and Subtitles. The titles and subtitles used in this Agreement are used
for convenience only and are not to be considered in construing or interpreting this Agreement. 
 4.9 Aggregation of Stock. All
shares of the Preferred Stock held or acquired by affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

4.10 Additional Parties. The Investors agree that, upon delivery of counterpart signature pages to this Agreement, any additional
persons who become “Investors” pursuant to the Series G Purchase Agreement shall become “Investors” and “Holders” under this Agreement without further action by any other Investor. 

4.11 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other person
and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with
respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Restated Certificate, or elsewhere, as the case may be. 

4.12 Foreign Investors. Notwithstanding anything to the contrary set forth herein, no Foreign Investor (as defined in the Purchase
Agreement), shall obtain any of the following rights (to the extent such Foreign Investor did not have such rights prior to the date of this Agreement): (i) access to any “material nonpublic technical information” (as defined in the DPA)
in the possession of the Company; (ii) membership or observer rights on the Board of Directors or equivalent governing body of the Company or the right to nominate an individual to a position on the Board of Directors or equivalent governing
body of the Company; (iii) any involvement, other than through the voting of shares, in the substantive decision-making of the Company regarding (x) the use, development, acquisition or release of any Company “critical
technology” (as defined in the DPA) or (y) the use development, acquisition, safekeeping or release of “sensitive personal data” (as defined in the DPA) of U.S. citizens maintained or collected by the Company; or (iv)
“control” of the Company (as defined in the DPA). 
 [Signature Pages Follow] 

 

  
 -17- 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	COMPANY
	
	ROBLOX CORPORATION
	a Delaware corporation
		
	By:	 	 /s/ David Baszucki

		 	 David Baszucki
 President and Chief Executive
Officer

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	ANDRESSEN HOROWITZ LSV FUND I, L.P.
		
	By:	 	 /s/ Ben Horowitz

		
	Name:	 	Ben Horowitz
		
	Title:	 	Member

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	TIGER GLOBAL PRIVATE INVESTMENT PARTNERS X, L.P.
	
	By: Tiger Global PIP Performance X, L.P.
	Its: General Partner
	
	By: Tiger Global PIP Management X, Ltd.
	Its: General Partner
		
	By:	 	 /s/ Steven Boyd

	Name:	 	Steven Boyd
	Title:	 	General Counsel

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

	
	EVAN FEINBERG
	
	 /s/ Evan Feinberg

	(Signature)

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	GREYLOCK 15 LIMITED PARTNERSHIP
		
	By:	 	Greylock 15 GP LLC, its General Partner
		
	By:	 	 /s/ Donald Sullivan

		 	Donald Sullivan, Partner

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	GREYLOCK 15-A LIMITED PARTNERSHIP
		
	By:	 	Greylock 15 GP LLC, its General Partner
		
	By:	 	 /s/ Donald Sullivan

		 	Donald Sullivan, Partner

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	GREYLOCK 15 PRINCIPALS LIMITED PARTNERSHIP
		
	By:	 	Greylock 15 GP LLC, its General Partner
		
	By:	 	 /s/ Donald Sullivan

		 	Donald Sullivan, Partner

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	INDEX VENTURES GROWTH III (JERSEY), L.P
		
	By:	 	Index Venture Growth Associates III
		 	Limited, its Managing General Partner

 
			
		
	By:	 	 /s/ N.T. Greenwood

			
	Printed Name:	 	/s/ N.T. Greenwood

 
			
	Title:	 	Director

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	YUCCA (JERSEY) SLP
		
	By:	 	EFG Trust Company Limited as Authorised Signatory of Yucca (Jersey) SLP in its capacity as administrator of the Index Ventures Growth III Co-Investment
Scheme

 
			
		
	By:	 	 /s/ N.T. Greenwood

			
	Printed Name:	 	N.T. Greenwood

 
			
	Title:	 	Authorized Signatory

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

	
	FIRST ROUND CAPITAL II, L.P.
	as nominee for
	First Round Capital II, L.P.
	First Round Capital II-A, L.P.
	First Round Capital II partners Fund, L.P.
	
	By: First Round Capital Management II, L.P.
	Its General Partner
	
	By: First Round Capital Management II, LLC
	Its General Partner
	
	 /s/ Josh Kopelman

	(Signature)
	
	 Josh Kopelman Partner

	 (Name and title of signatory, if applicable)

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	ALTOS VENTURES IV, L.P.
	
	By: Altos Management Partners IV, LLC its General Partner
		
	By:	 	 /s/ Anthony Lee

	Name:	 	Anthony Lee
	Title:	 	Managing Director

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	ALTOS VENTURES IV LIQUIDITY FUND, L.P.
		
	By:	 	Altos Management Partners IV, LLC,
		 	its general partner
		
	By:	 	 /s/ Anthony Lee

	Name:	 	Anthony Lee
	Title:	 	Managing Director

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	ALTOS ROBLOX SPV 1, LLC
		
	By:	 	Altos Roblox Management Partners, LLC,
		 	its general partner
		
	By:	 	 /s/ Anthony Lee

	Name:	 	Anthony Lee
	Title:	 	Managing Director

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	ALTOS ROBLOX SPV 2, LLC
		
	By:	 	Altos Roblox Management Partners, LLC,
		 	its general partner
		
	By:	 	 /s/ Anthony Lee

	Name:	 	Anthony Lee
	Title:	 	Managing Director

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	Altos Hybrid 2, L.P.
		
	By:	 	Altos Hybrid 2 GP, LLC,
		 	its general partner
		
	By:	 	 /s/ Anthony Lee

	Name:	 	Anthony Lee
	Title:	 	Managing Director

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	ALTOS ROBLOX SPV 2020, LLC
		
	By:	 	Altos Roblox 2020 Management Partners, LLC,
		 	its general partner

 
			
		
	By:	 	 /s/ Anthony Lee

	Name:	 	Anthony Lee
	Title:	 	Managing Director

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	ALTOS VENTURES IV RESERVE FUND, L.P.
		
	By:	 	Altos Management Partners IV, LLC,
		 	its general partner

 
			
		
	By:	 	 /s/ Anthony Lee

	Name:	 	Anthony Lee
	Title:	 	Managing Director

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	THE FREEDOM REVOCABLE TRUST DATED FEBRUARY 28, 2017 AS AMENDED
		
	By:	 	 /s/ David Baszucki

		 	David Baszucki, Trustee

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	MERITECH CAPITAL PARTNERS V L.P.
		
	By:	 	Meritech Capital Associates V L.L.C.
		 	its General Partner
		
	By:	 	 /s/ Craig Sherman

		 	Craig Sherman, a managing member

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	MERITECH CAPITAL AFFILIATES V L.P.
		
	By:	 	Meritech Capital Associates V L.L.C.
		 	its General Partner
		
	By:	 	 /s/ Craig Sherman

		 	Craig Sherman, a managing member

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	MERITECH CAPITAL PARTNERS V SIDECAR L.P.
		
	By:	 	Meritech Capital Associates V L.L.C.
		 	its General Partner
		
	By:	 	 /s/ Craig Sherman

		 	Craig Sherman, a managing member

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

			
	INVESTOR
	
	Anderson Investments Pte Ltd.
		
	By:	 	/s/ Ang Peng Huat

 
			
	Printed Name:	 	Ang Peng Huat

 
			
	Title:	 	Authorised Signatory

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement on the day and year first set forth above. 
  

	
	 /s/ Jason Schneider

	JASON SCHNEIDER

  

  
 ROBLOX CORPORATION

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 EXHIBIT A 

INVESTORS 
  

			
	 Name and Address
	 	 
	Greylock 15 Limited Partnership	 	
		
	Greylock 15-A Limited Partnership	 	
		
	Greylock 15 Principals Limited Partnership	 	
		
	Seth Rosenberg	 	
		
	Tiger Global Private Investment Partners X, L.P.	 	
		
	LFX Capital LLC	 	
		
	 Meritech Capital Partners V L.P.
 Meritech
Capital Partners V Sidecar L.P.
 Meritech Capital Affiliates V L.P.
	 	
		
	YUCCA (JERSEY) SLP	 	
		
	INDEX VENTURES GROWTH III (JERSEY), L.P	 	
		
	 The Greg and Christina Baszucki Living Trust

Agreement dtd 8/18/2006
	 	
		
	 The Paul and Helen Baszucki Revocable Trust dtd

October 19, 2006
	 	
		
	The Paul and Helen Baszucki Family LP	 	
		
	 The Freedom Revocable Trust Dated February 28, 2017

as amended
	 	
		
	Todd Baszucki	 	

			
	Greg Baszucki	 	
		
	Don C. Bice	 	
		
	First Round Capital II, L.P.	 	
		
	David and Edith Cassel	 	
		
	Charlotte A. Golinvaux Trust	 	
		
	Comstock Investments, Inc.	 	
		
	C. C. Dunnavan Tamarak Irrevocable 2005 Trust	 	
		
	Charles C. Dunnavan	 	
		
	Susan Elmore	 	
		
	 G.A.S. Roblox, LLC
 G.A.S. Roblox One,
LLC
	 	
		
	John P. & Maureen F. Golinvaux Children’s Trust	 	
		
	John P. Golinvaux	 	
		
	James V. Golinvaux	 	
		
	Lou Golinvaux	 	
		
	Jerome T. Golinvaux Trust	 	
		
	David P. Golinvaux Trust	 	
		
	J. Thomas Golinvaux, Jr. Trust	 	
		
	C. Wayne LeNeave	 	

			
	Cindy and Cuyler Morris	 	
		
	Bob Pajor	 	
		
	Mario M. Rosati	 	
		
	 The San Domenico Trust
 UDT dated
August 12, 1999
	 	
		
	Neil I. Sell	 	
		
	Allen L. Taylor	 	
		
	Steve Wexler	 	
		
	Katherine A. Wilson	 	
		
	 WS Investment Company, LLC (2007A)
 WS
Investment Company, LLC (2009A)
	 	
		
	Altos Ventures IV, L.P.	 	
		
	 Altos Roblox SPV 2020, LLC
 Altos Ventures IV
Reserve Fund, L.P.
 Altos Hybrid 2, L.P.
 Altos Roblox SPV 1.
LLC
 Altos Roblox SPV 2, LLC
 Altos Ventures IV Liquidity Fund,
L.P.
	 	
		
	The Craig Douglas Sherman Trust	 	
		
	 Andreessen Horowitz LSV Fund I, L.P., for itself and as nominee for

Andreessen Horowitz LSV Fund I-B, L.P. and

Andreessen Horowitz LSV Fund I-Q, L.P.
	 	
		
	CLF Partners, LP	 	

			
		
	Jason Schneider	 	
		
	Anderson Investments Pte Ltd.	 	
		
	TCH Scarlet Limited, an Irish Company	 	

 SCHEDULE 1 

NOTICE AND WAIVER/ELECTION OF 

RIGHT OF FIRST REFUSAL 

I do hereby waive or exercise, as indicated below, my rights of first refusal under the Amended and Restated Investors’ Rights
Agreement dated as of February 27, 2020 (the “Agreement”): 
  

	1.	 Waiver of 10 days’ notice period in which to exercise right of first refusal: (please check only
one) 

  

	 	(    )	 WAIVE in full, on behalf of all Holders, the 10-day notice
period provided to exercise my right of first refusal granted under the Agreement. 

  

	 	(    )	 DO NOT WAIVE the notice period described above. 

 

	2.	 Issuance and Sale of New Securities: (please check only one) 

 

	 	(    )	 WAIVE in full the right of first refusal granted under the Agreement with respect to the issuance of the
New Securities. 

  

	 	(    )	 ELECT TO PARTICIPATE in $__________ (please provide amount) in New Securities proposed to be
issued by Roblox Corporation, a Delaware corporation, representing LESS than my pro rata portion of the aggregate of $[_______] in New Securities being offered in the financing. 

 

	 	(    )	 ELECT TO PARTICIPATE in $__________ in New Securities proposed to be issued by Roblox Corporation, a
Delaware corporation, representing my FULL pro rata portion of the aggregate of $[_______] in New Securities being offered in the financing. 

  

	 	(    )	 ELECT TO PARTICIPATE in my full pro rata portion of the aggregate of $[_______] in New Securities
being made available in the financing AND, to the extent available, the greater of (x) an additional $__________ (please provide amount) or (y) my pro rata portion of any remaining investment amount available in the event
other Significant Holders do not exercise their full rights of first refusal with respect to the $[_______] in New Securities being offered in the financing. 

 

					
	 Date: ________________
	 	
                
	  	  

		 		  	(Print investor name)
			
		 		  	  

		 		  	(Signature)
			
		 		  	  

		 		  	(Print name of signatory, if signing for an entity)
			
		 		  	  

		 		  	(Print title of signatory, if signing for an entity)

 This is neither a commitment to purchase nor a commitment to issue the New Securities described above. Such issuance can
only be made by way of definitive documentation related to such issuance. The company will supply you with such definitive documentation upon request or if you indicate that you would like to exercise your first offer rights in whole or in part.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]